Please assess the completion status of the following clinical trial:

Trial Title: Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed breast cancer, meeting 1 of the following stage criteria:~  * Stage IIB (T3, N0)~ * Stage IIIA (N0-N2)~ * Stage IIIB (T4, N0-2)~ * Stage IIIC~ * Inflammatory breast cancer~* HER2/neu-positive disease by fluorescence in situ hybridization~* Biopsy-accessible tumor~* Measurable disease by physical examination or x-ray~* No stage IV disease~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age~* 18 and over~Sex~* Female~Menopausal status~* Not specified~Performance status~* ECOG 0-2~Life expectancy~* At least 8 weeks~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic~* Meets 1 of the following criteria:~  * SGOT and SGPT ≤ 5 times upper limit of normal (ULN) AND alkaline phosphatase normal~ * SGOT and SGPT ≤ 1.5 times ULN AND alkaline phosphatase ≤ 2.5 times ULN~ * SGOT and SGPT normal AND alkaline phosphatase ≤ 5 times ULN~* Bilirubin normal~Renal~* Creatinine normal~* No pre-existing clinically significant renal disease that is not related to the malignancy~Cardiovascular~* Ejection fraction ≥ 50% by MUGA~* No pre-existing clinically significant cardiac disease that is not related to the malignancy~* No history of congestive heart failure~Pulmonary~* No pre-existing clinically significant pulmonary disease that is not related to the malignancy~Gastrointestinal~* No severe malnutrition~* No intractable emesis~Neurologic~* No pre-existing clinically significant neurologic disease that is not related to the malignancy~* No peripheral neuropathy ≥ grade 2~  * No nerve damage from diabetes~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective non-hormonal contraception during and for 4 weeks after completion of study treatment~* No known allergic reaction to study drugs~* No active infection~* No other malignancy except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* No other pre-existing clinically significant disease that is not related to the malignancy~* No other serious or significant medical condition that would preclude study participation~* No other contraindication to study treatment~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No other concurrent immunotherapy~Chemotherapy~* No prior chemotherapy for the malignancy~* No other concurrent chemotherapy~Endocrine therapy~* No concurrent hormonal therapy for the malignancy~Radiotherapy~* No concurrent radiotherapy~Surgery~* No concurrent surgery for the malignancy~Other~* More than 2 weeks since prior and no concurrent herbal remedies or aspirin-containing products~* No other concurrent investigational or commercial agents or therapies for the malignancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Docetaxel, Carboplatin and Trastuzumab (Type: EXPERIMENTAL): A total of six cycles of TCH \[(Taxotere® (75 mg/m2) + Carboplatin (AUC = 6) + Herceptin® (2 mg/kg weekly after a 4 mg/kg load on Day 1)\] will be administered every 3 weeks.Three weeks after receiving the sixth cycle of TCH, all patients will be restaged.~* Those determined to have localized and operable disease (as determined by surgical consultation) will undergo a modified radical mastectomy or lumpectomy and axillary node dissection. After recovery from surgery, the patients will receive whole breast or chest wall irradiation (as determined by radiologist) with concurrent Herceptin® (6 mg/kg). Following radiation, patients will continue Herceptin® (6 mg/kg) every 3 weeks until they have been on study for a total of 52 weeks.~* If patients are staged and are negative they will continue Herceptin® (6 mg/kg)every 3 weeks until they have been on study for a total of 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).